-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Goli Pharmaceutical-B (01672.HK) announced that the company's board of directors will report in the form of a brief oral discussion at the 62nd European Diabetes Research Association (EASD) annual meeting in Milan, Italy, on the preclinical data of ASC36_35 FDC for the treatment of obesity, that is, ASC36 (a polypeptide pancreatin receptor agonist) and ASC35 (a polypeptide GLP-1R/GIPR agonist). The data showed that in animal models of diet-induced obesity (DIO), the drug showed superior weight loss effects compared with the combined administration of eloralintide and tiverpotide.

Zhitongcaijing·07/23/2026 00:09:03
Listen to the news
Zhitong Financial App News, Goli Pharmaceutical-B (01672.HK) announced that the company's board of directors will report in the form of a brief oral discussion at the 62nd European Diabetes Research Association (EASD) annual meeting in Milan, Italy, on the preclinical data of ASC36_35 FDC for the treatment of obesity, that is, ASC36 (a polypeptide pancreatin receptor agonist) and ASC35 (a polypeptide GLP-1R/GIPR agonist). The data showed that in animal models of diet-induced obesity (DIO), the drug showed superior weight loss effects compared with the combined administration of eloralintide and tiverpotide.